Core Viewpoint - Karolinska Development AB held an Extraordinary General Meeting on January 8, 2026, where significant resolutions were made regarding share capital increase and company name change [1]. Group 1: Share Capital Increase - The Board of Directors' resolution to issue new shares with preferential rights for existing shareholders was approved, allowing an increase in share capital by up to SEK 6,751,939.85 through a rights issue of no more than 675,193,985 shares of series B [2]. - Each existing share entitles shareholders to five subscription rights, with two subscription rights allowing the subscription of one new share of series B at a price of SEK 0.30 per share [3]. Group 2: Subscription Period - The subscription period for the rights issue is set from January 13, 2026, to January 27, 2026 [4]. Group 3: Amendments to Articles of Association - The company name will be changed to KDventures AB, and amendments were made to the object of the Company's business, with share capital limits set between SEK 2,650,000 and SEK 10,600,000, and the number of shares limited to between 265,000,000 and 1,060,000,000 [5]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [8]. - The company has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around leading scientists supported by experienced management teams [9]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, led by a team of investment professionals with a strong track record [10].

Core Viewpoint - Karolinska Development AB emphasizes its clear strategy and stable scientific foundation for its investment portfolio, focusing on patient benefits amidst challenging market conditions [1]. Significant Events - Organon plans to discontinue the clinical development of drug candidate OG-6219, following Phase 2 study results [3]. - Umecrine Cognition presented preclinical data on golexanolone's effects on Parkinsonian symptoms at the AD/PD 2025 conference [4]. - Umecrine Cognition received a USD 420,000 research grant from The Michael J. Fox Foundation for golexanolone studies [4]. - OssDsign achieved a milestone of treating 10,000 patients with its bone graft product in the US market [4]. - Karolinska Development divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million [4]. Financial Update - The net profit/loss for Q2 2025 was SEK -73.3 million, compared to SEK -16.0 million in Q2 2024 [5]. - The total fair value of the portfolio decreased to SEK 1,384.9 million at the end of June 2025, down from SEK 1,434.2 million [5]. - Net asset value at the end of June 2025 was SEK 1,148.6 million, or SEK 4.3 per share, compared to SEK 1,238.2 million, or SEK 4.6 per share, at the end of June 2024 [5]. - Cash and cash equivalents increased by SEK 20.0 million, totaling SEK 71.1 million on June 30, 2025 [5].